Addex R&D Day Highlights
(Thomson Reuters ONE) -
Addex Pharmaceuticals / Addex R&D Day Highlights processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Terms of schizophrenia deal with Ortho-McNeil-Janssen Pharmaceuticals, Inc.
disclosed for the first time
Oral GLP-1 receptor positive allosteric modulator effective in preclinical
models of diabetes
mGluR4 positive allosteric modulators demonstrate efficacy in preclinical model
of anxiety
IL-1 receptor negative allosteric modulators identified
Geneva, Switzerland, 11 May 2010 - Allosteric modulation company Addex
Pharmaceuticals Ltd (SIX:ADXN) is holding its annual R&D Day today at its
headquarters starting at 11am CET. Webcasts of the presentations will be
available in live and recorded forms via www.addexpharma.com
"The exciting progress in our programs partnered with Ortho-McNeil-Jansen
Pharmaceuticals, Inc. and Merck & Co., Inc., as well as the innovative
breakthroughs in un-partnered discovery programs show that the fundamentals of
our platform for allosteric drug discovery and development are stronger than
ever," CEO Vincent Mutel said.
The company will discuss new data and/or the status of multiple clinical and
preclinical stage programs including:
· ADX48621 is scheduled to start in 2010 Phase II testing in patients
with Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Phase IIa
testing in patients with dystonia. ADX48621 is an mGluR5 negative allosteric
modulator (NAM) wholly owned by Addex. Inhibition of mGluR5 is a clinically
validated mechanism in PD-LID.
· ADX71149 is expected to start Phase IIa testing for schizophrenia and
anxiety in 2010, subject to the successful completion of the ongoing Phase I
program and regulatory approvals. Addex disclosed today for the first time that,
under the terms of the partnership with Ortho-McNeil-Janssen Pharmaceuticals,
Inc. (OMJPI), Addex is eligible for up to ?112 million subject to successful
completion of development and regulatory milestones. In addition, Addex is
eligible for low double-digit royalties on sales of ADX71149, subject to
regulatory approval and successful commercial launch. ADX71149 is an mGluR2
positive allosteric modulator (PAM) being developed by OMJPI. Activation of
mGluR2 is a clinically validated mechanism in both schizophrenia and anxiety.
· Data released today for the first time, from the collaboration with
Merck & Co., Inc. to develop mGluR4 PAM for treatment of Parkinson's disease and
other indications, show that orally available mGluR4 PAM reduced anxiety in a
preclinical model. Parkinson's disease patients often suffer from anxiety and
depression.
· Data released today for the first time, show that GLP-1 receptor
(GLP1R) PAM significantly enhanced insulin secretion and significantly reduced
the rise in plasma glucose following glucose administration in the "db/db"
preclinical model of Type II diabetes.
· Addex disclosed today for the first time that it has identified IL-1
receptor (IL1R) negative allosteric modulators and, in using its proprietary
screening tool, ADX-tags 1, identified as an IL1R NAM a known anti-inflammatory
molecule, which had not previously been identified as an IL1R antagonist.
Addex Pharmaceuticals (www.addexpharma.com
discovers and develops allosteric modulators for human health and is focused on
validated therapeutic targets for diseases of the central nervous system,
metabolic disorders and inflammation. Subject to the completion of Phase I
testing and regulatory approvals, Phase II clinical trials are expected to start
in 2010 in four indications for two lead products: ADX48621, an mGluR5 negative
allosteric modulator (NAM), in dystonia and Parkinson's disease levodopa-induced
dyskinesia (PD-LID); and ADX71149, an mGluR2 positive allosteric modulator
(PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-B receptor
PAM with potential for chronic pain, is scheduled to enter Phase I testing
around the end of 2010. In addition, Merck & Co., Inc. has licensed rights to
two preclinical products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for
schizophrenia. Additional preclinical discovery stage programs include: mGluR2
NAM, GLP1R PAM, IL1R1 NAM and TNFR1 NAM. Roche Venture Fund and SR-One,
corporate venture arm of GlaxoSmithKline, are investors in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
[HUG#1414467]
--- End of Message ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
ISIN: CH0029850754;
Français (PDF) : http://hugin.info/138017/R/1414467/365799.pdf
English (pdf): http://hugin.info/138017/R/1414467/365798.pdf
Deutsch (PDF) : http://hugin.info/138017/R/1414467/365800.pdf
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2010 - 07:02 Uhr
Sprache: Deutsch
News-ID 20623
Anzahl Zeichen: 0
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex R&D Day Highlights"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
